



ERRATUM

**Disclosure of Share Capital and Voting Rights
Outstanding as of December 31, 2010**

**(Pursuant to Article L.233-8 II of the French Commercial Code
and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers)**

Charenton-le-Pont, France (January 10, 2011) – This news release corrects and replaces the previous press release issued on January 6. The changes concern the figures in the table.

As of December 31, 2010, shares and voting rights outstanding of Essilor, the world leader in ophthalmic optics, broke down as follows:

	December 31, 2010
Shares outstanding	211,655,342
Exercisable voting rights	226,999,731
Total voting rights, based on all outstanding shares, including shares stripped of their voting rights*	229,893,843

*Shares held by the Company, either in treasury or under the liquidity contract.

The world leader in ophthalmic optical products, Essilor International researches, develops, manufactures and markets around the world a wide range of lenses to correct myopia, hyperopia, presbyopia and astigmatism. Its flagship brands are Varilux[®], Crizal[®], Essilor[®], Definity[®] and Xperio[™].

Based in France, the company reported consolidated revenue of €3.2 billion in 2009, with 34,700 employees and operations in 100 countries.

For more information, please visit www.essilor.com.

The Essilor share trades on the NYSE Euronext Paris market and is included in the CAC 40 index. Codes and symbols: ISIN: FR FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.

Investor Relations and Financial Communications

Phone: +33 (0)1 49 77 42 16